The biochemical raw material of Vonola fumarate has been approved for marketing
August 15, 2025
Source: drugdu
79
People's Finance News, August 13th: China National Pharmaceutical Group (600056) announced on the evening of August 13th that its wholly-owned subsidiary, Tianfang Pharmaceutical, has received the "Notice of Approval for the Marketing Application of Vonoprazan fumarate" issued by the National Medical Products Administration. This medicine is mainly used to treat reflux esophagitis. Combined with appropriate antibiotics to eradicate Helicobacter pylori.
In addition, Tianfang Pharmaceutical has recently received the "European Pharmacopoeia Applicability" certificate for clindamycin phosphate approved and issued by the European Agency for the Quality of Medicines. This medicine is a lincomycin antibiotic, mainly used for infections caused by Gram-positive bacteria and anaerobic bacteria.
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for marketing authorization of trivalent influenza virus split vaccine has been accepted October 8, 2025
- Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion. October 8, 2025
- Zhifei Bio’s independent product, influenza virus split vaccine, has obtained a drug registration certificate October 8, 2025
- Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease October 7, 2025
- Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks October 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
